Takano Gaku, Kawakita Daisuke, Iwata Hiromitsu, Hattori Yukiko, Nakajima Koichiro, Tsuzuki Yusuke, Sudo Shuou, Toshito Toshiyuki, Hayashi Kensuke, Matoba Takuma, Sawabe Michi, Minohara Kiyoshi, Iwaki Sho, Nakai Kazuyuki, Iwase Yu, Iwasaki Shinichi, Ogino Hiroyuki
Department of Otorhinolaryngology, Nagoya City University West Medical Center, Nagoya, Japan.
Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Head Neck. 2025 Aug;47(8):2313-2323. doi: 10.1002/hed.28149. Epub 2025 Mar 31.
In recent years, particle therapy has shown promise as a local treatment for salivary gland carcinoma (SGC); however, its efficacy and safety remain unclear. This study aimed to evaluate the clinical outcomes of intensity-modulated proton therapy (IMPT) for SGC.
We performed a single-institution retrospective analysis of patients with SGC who underwent IMPT.
IMPT was performed on 28 SGC patients, of which 18 were for definitive treatment and 10 were for postoperative treatment. The 2-year overall survival (OS), progression-free survival (PFS), and local control (LC) rates for definitive treatment cases were 70.1%, 25.0%, and 82.5%, respectively. The 2-year OS, PFS, and LC rates for postoperative treatment cases were 100%, 80.0%, and 90.0%, respectively. Quality of life scores in the EORTC QLQ-C30 and QLQ-HN35 were preserved for 1 year after treatment.
Our study suggests the efficacy and safety of IMPT in SGC patients.
近年来，粒子治疗已显示出有望成为唾液腺癌（SGC）的局部治疗方法；然而，其疗效和安全性仍不明确。本研究旨在评估调强质子治疗（IMPT）对SGC的临床疗效。
我们对接受IMPT的SGC患者进行了单机构回顾性分析。
对28例SGC患者实施了IMPT，其中18例为根治性治疗，10例为术后治疗。根治性治疗病例的2年总生存率（OS）、无进展生存率（PFS）和局部控制率（LC）分别为70.1%、25.0%和82.5%。术后治疗病例的2年OS、PFS和LC率分别为100%、80.0%和90.0%。治疗后1年内，欧洲癌症研究与治疗组织QLQ-C30和QLQ-HN35中的生活质量评分得以保留。
我们的研究表明IMPT对SGC患者具有疗效和安全性。
